Table 1.
Patient characteristics (n = 42).
| Characteristics | Median (range); n (%) |
|---|---|
| Age at PCa diagnosis | 65.5 (49–84) |
| Initial PSA (ng/ml) | 9.8 (3.7–84.5) |
| Primary therapy | |
| RPE alone | 11 (26.2) |
| RPE +aRT | 13 (31.0) |
| RPE + sRT | 14 (33.3) |
| EBRT + temporary ADT | 4 (9.5) |
| Initial T stage | |
| cT1c | 5 (11.9) |
| pT2a,b | 4 (8.1) |
| pT2c | 13 (31.0) |
| pT3a | 7 (16.7) |
| pT3b | 11 (26.2) |
| pT4 a,b | 0 |
| unknown | 2 (4.8) |
| Gleason-Score | |
| 7a | 8 (19.0) |
| 7b | 10 (23.8) |
| 8 | 13 (31.0) |
| 9 | 11 (26.2) |
| Initial N stage | |
| N0 | 30 (71.4) |
| N1 | 8 (19.0) |
| Surgical margins | |
| R0 | 34 (81.0) |
| R1 | 4 (9.5) |
| unknown | 4 (9.5) |
| Initial risk group | |
| Low Risk | 0 |
| Intermediate Risk | 9 (21.4) |
| High Risk | 31 (73.8) |
| unknown | 2 (4.8) |
| PSA nadir after definitive therapy (ng/ml) | 0.07 (<0.07–5.2) |
| Interval (m) from definitive therapy to PSMA PET | 76 (19–178) |
| PSA level at PSMA ligand PET imaging (ng/ml) | 4.79 (0.4–46.1) |
| Patients with ADT at PSMA ligand PET imaging | 42 (100%) |
| Median Duration of ADT at time of PSMA-PET imaging (m) | 40.0 (12–180) |
| Median PSA dt at time of PSMA-PET imaging (m) | 7.6 (3.6–50.5) |
ADT, androgen deprivation therapy; aRT, adjuvant radiotherapy; dt, doubling time, EBRT, external beam radiation therapy; m, months; PCa, prostate cance;, PSMA ligand PET, prostate-specific membrane antigen ligand positron emission tomography; PSA, prostate-specific antigen; m, months; RP, radical prostatectomy; sRT, salvage radiotherapy.